Pharmacovigilance

Pharmaceutical companies could slash their pharmacovigilance costs by half while significantly improving accuracy through generative AI, according to IQVIA’s Global Practice Lead of Pharmacovigilance Technologies, Uwe Trinks. “The idea is: we can save 50% of the cost and get the quality to above 99%,” Trinks said. “That means when we have human verification, we only…

Biogen’s Tysabri (natalizumab), the first humanized monoclonal antibody for multiple sclerosis (MS), sparked optimism among MS patients following its FDA approval in 2004. The drug offered significant benefits, reducing relapses for patients resistant to other treatments. This was a significant milestone in the treatment of MS, but the journey of natalizumab and PML soon took…